CG Oncology (NASDAQ:CGON) Given New $85.00 Price Target at Piper Sandler

CG Oncology (NASDAQ:CGON) had its target price lifted by Piper Sandler from $82.00 to $85.00 in a research note released on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts also recently issued reports on the company. Wall Street Zen downgraded CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Friday, July 17th. JPMorgan Chase & Co. lifted their target price on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of CG Oncology in a report on Wednesday, July 29th. Finally, Truist Financial raised their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $83.18.

CG Oncology Trading Up 0.3%

NASDAQ:CGON opened at $75.10 on Friday. The company has a 50-day moving average of $67.12 and a 200-day moving average of $63.95. The firm has a market cap of $6.62 billion, a price-to-earnings ratio of -27.92 and a beta of 0.23. CG Oncology has a twelve month low of $23.65 and a twelve month high of $77.00.

CG Oncology (NASDAQ:CGON) last released its earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 26.58%. On average, research analysts forecast that CG Oncology will post -2.89 earnings per share for the current year.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total transaction of $350,000.00. Following the completion of the sale, the director directly owned 5,000 shares in the company, valued at approximately $350,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Brian Guan-Chyun Liu purchased 371,085 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average price of $66.87 per share, with a total value of $24,814,453.95. Following the completion of the acquisition, the director owned 1,886,236 shares of the company’s stock, valued at $126,132,601.32. This trade represents a 24.49% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 37,129 shares of company stock valued at $2,663,817 over the last three months. 4.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CG Oncology

A number of hedge funds have recently modified their holdings of the stock. NFSG Corp acquired a new stake in shares of CG Oncology during the 1st quarter valued at about $34,000. Comerica Bank increased its holdings in CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after buying an additional 515 shares during the last quarter. LPL Financial LLC raised its position in CG Oncology by 9.8% during the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock valued at $257,000 after acquiring an additional 551 shares in the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new stake in CG Oncology in the fourth quarter valued at approximately $27,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in CG Oncology by 33.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after acquiring an additional 972 shares during the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about CG Oncology

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $82 to $85 and assigned an “overweight” rating, implying approximately 13.2% upside. Benzinga
• Positive Sentiment: Truist Financial also raised its target from $82 to $85 and upgraded its view to “buy,” citing a more constructive outlook for CG Oncology. The Fly
• Positive Sentiment: HC Wainwright maintained a “buy” rating and a $100 target. The firm modestly increased its long-term FY2030 EPS forecast to $6.88 from $6.77, reinforcing expectations for significant future earnings growth as the company advances its pipeline. MarketBeat
• Positive Sentiment: CG Oncology reported second-quarter revenue of $1.16 million, substantially above the $0.36 million consensus estimate, while also highlighting pipeline and business progress. CG Oncology Second-Quarter Results
• Neutral Sentiment: Royal Bank of Canada lowered its target from $81 to $79 but retained an “outperform” rating. The reduced target still represents roughly 5.2% potential upside and may reflect valuation calibration rather than a fundamental downgrade. Ticker Report
• Negative Sentiment: CG Oncology reported a quarterly loss of $0.90 per share, wider than the $0.66 consensus loss and the $0.54 loss recorded a year earlier. The earnings shortfall could limit gains despite strong analyst targets. Zacks Q2 Earnings Report
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS estimate from $2.43 to $2.34, signaling some moderation in its intermediate-term earnings outlook, although its buy rating and $100 target remain unchanged.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.